Table 1

Characteristics of trials of LC for CKD-MBD in dialysis patients
Study Intervention No. of patients Duration (Week) Dialysis methods
LC group Control group
Fouad Al-Baaj 2005 LC 375-2250 mg/d Placebo 36 4 HD
Melanie S. Joy 2003 LC 375 mg, 750 mg, 1500 mg, 2250 mg, 3000 mg/day Placebo 93 4 HD and CAPD
Finn WF 2006 LC<3000 mg/d (serum phosphate ≤5.9 mg/dl) pre-study phosphate binder (serum phosphate ≤5.9 mg/dl) 1359 104 HD
Patrick. C 2003 LC<3750 mg/d CC<9000 mg/d 98 52 HD
N. D TOUSSAINT 2011 LC (serum phosphate in the normal range) CC (serum phosphate in the normal range) 45 72 HD and CAPD
T.shigematsu 2008 LC+CC-liked placebo 750, 1500, 2250 mg/d (serum phosphate at 3.5-5.5 mg/dl) CC+LC-liked placebo 1500, 3000, 4500 mg/d(serum phosphate 3.5-5.5 mg/dl) 258 8 HD
H H Mallache 2008 LC<3000mg/d (serum phosphate≤5.9mg/dl) Previous phosphate binder (serum phosphate ≤5.9 mg/dl) 65 52 HD
T.shigematsu 2007 LC 750 mg, 1500 mg, 2250 mg, 3000 mg/day Placebo 142 6 HD
Spasovski GB 2006 LC<3000 mg/d (serum phosphate <1.8 mmol/L) CC< 4000 mg/d (serum phosphate <1.8 mmol/L) 24 52 Not describe
A.J. Hutchison 2005 LC 250-3000 mg/d CC 1000-9000 mg/d 767 25 HD
S.-S. Chiang 2005 LC 375-3000 mg/d (can’t change during study) Placebo 61 4 HD
Finn WF 2004 LC 225 mg, 675 mg, 1350 mg, 2250 mg/day Placebo 144 6 HD
Yong Kyu Lee 2013 LC 1500 mg at start, regulate to control the serum phosphate at 3.5-5.5 mg/dl CC 3000 mg at start, regulate to control the serum phosphate at 3.5-5.5 mg/dl 50 24 CAPD
Xu 2013 LC 1500 mg-3000 mg/day Placebo 230 4 HD and CAPD
Sprague S.M 2009 LC 3,000 mg/day SH 6,400 mg/day 333 4 HD
Kasai S 2012 LC 375–2250 mg/day SH 750–9000 mg/day 84 13 HD

Zhang et al.

Zhang et al. BMC Nephrology 2013 14:226   doi:10.1186/1471-2369-14-226

Open Data